ProKidney (NASDAQ:PROK – Get Free Report) and Xencor (NASDAQ:XNCR – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability.
Profitability
This table compares ProKidney and Xencor’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProKidney | -10,288.39% | N/A | -27.39% |
| Xencor | -58.79% | -21.28% | -15.17% |
Valuation & Earnings
This table compares ProKidney and Xencor”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ProKidney | $818,000.00 | 417.63 | -$68.99 million | ($0.55) | -2.05 |
| Xencor | $125.58 million | 23.88 | -$91.92 million | ($1.59) | -25.14 |
ProKidney has higher earnings, but lower revenue than Xencor. Xencor is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
ProKidney has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500. Comparatively, Xencor has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations for ProKidney and Xencor, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProKidney | 1 | 0 | 2 | 1 | 2.75 |
| Xencor | 1 | 3 | 6 | 1 | 2.64 |
ProKidney presently has a consensus target price of $10.00, suggesting a potential upside of 784.96%. Xencor has a consensus target price of $42.22, suggesting a potential upside of 5.63%. Given ProKidney’s stronger consensus rating and higher possible upside, equities analysts clearly believe ProKidney is more favorable than Xencor.
Insider and Institutional Ownership
51.6% of ProKidney shares are held by institutional investors. 39.8% of ProKidney shares are held by insiders. Comparatively, 5.1% of Xencor shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
ProKidney beats Xencor on 10 of the 14 factors compared between the two stocks.
About ProKidney
ProKidney is a clinical-stage biotechnology company developing cell therapies for people with chronic kidney disease. The company’s work focuses on treatments intended to help preserve kidney function, particularly in patients with diabetic kidney disease. Its lead investigational product, REACT (REnal Autologous Cell Therapy), is made from cells collected from a patient’s own kidney tissue. The cells are processed and delivered back to the patient’s kidney. REACT is being evaluated in clinical trials and is not an approved treatment.
About Xencor
Xencor, Inc. is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for cancer and autoimmune diseases. The company’s XmAb technology platform modifies antibody structures to create treatments with properties such as enhanced immune-cell activity or the ability to bind to more than one target. Xencor advances its own drug candidates and works with other biopharmaceutical companies through research collaborations and licensing agreements. Its development programs include antibody-based approaches designed to engage immune cells or block disease-related targets.
Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.
